

International Congress for Lung Cancer, and Head & Neck Cancer

New York • September 25-26, 2009

New York Marriott East Side

525 Lexington Avenue at 49th Street
New York, NY 10017
Phone: (800) 242-8684

Program Director

Chandra P. Belani, MD

Miriam Beckner Distinguished Professor of Medicine
Penn State Milton S. Hershey Medical Center
Penn State College of Medicine
Deputy Director, Penn State Cancer Institute, Hershey, PA

Target Audience

This symposium is directed primarily to medical oncologists, radiation oncologists, surgical oncologists, researchers and registered oncology nurses interested in new developments for treatment of lung cancer. No specific skill or knowledge other than a basic training in oncology is required for successful participation in this activity. Fellows, nurses and pharmacists are also invited to attend.

Statement of Need/Program Overview

This Symposium is intended to provide comprehensive updates on biology, diagnosis, screening, and management of lung cancer. Paradigm shift in the treatment options of non-small-cell lung cancer and small-cell lung cancer will be discussed. This meeting will facilitate interaction among oncologists and researchers interested in development of novel therapeutics for treatment of lung cancer. In addition to multimodality therapy, adjuvant therapy and surgery, this symposium will present data of most promising emerging agents currently in development for the treatment of lung cancer. The format will include didactic lectures from known thought leaders, questions and answer session, and ample opportunity for participant interaction with faculty. In-depth discussion of antiangiogenic agents, inhibitors of EGFR pathways and drugs that target multiple signaling pathways will also be given significant focus. Emerging data from ongoing clinical research will be presented.

Physician Continuing Education

Accreditation Statement

This activity has been planned and implemented in accordance with the Essential Areas and policies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint sponsorship of Postgraduate Institute for Medicine (PIM) and International Cancer Network. PIM is accredited by the ACCME to provide continuing medical education for physicians.

Credit Designation

Postgraduate Institute for Medicine designates this educational activity for a maximum of 9.25 AMA PRA Category 1 Credit(s)[™]. Physicians should only claim credit commensurate with the extent of their participation in the activity.

Nursing Continuing Education

ANCC

Accreditation Statement

Postgraduate Institute for Medicine is accredited as a provider of continuing nursing education by the American Nurses Credentialing Center's Commission on Accreditation.

Credit Designation

This educational activity for 9.0 contact hours is provided by Postgraduate Institute for Medicine (PIM).

A statement of credit will be issued only upon receipt of a completed activity evaluation form, and will be mailed within six weeks.

Disclosure of Conflicts of Interest

Postgraduate Institute for Medicine (PIM) requires instructors, planners, managers and other individuals who are in a position to control the content of this activity to disclose any real or apparent conflict of interest they may have as related to the content of this activity. All identified conflicts of interest are thoroughly vetted by PIM for fair balance, scientific objectivity of studies mentioned in the materials or used as the basis for content, and appropriateness of patient care recommendations.

Americans with Disabilities Act

Event staff will be glad to assist you with any special needs (ie, physical, dietary, etc). Please contact Roberta Granny prior to the live event at (412) 491-7492.

Jointly sponsored by International Lung Cancer Network and Postgraduate Institute for Medicine

First Name _____ Middle Initial _____ Last Name _____

Physician Pa-C Fellow NP PhD Pharmacist Industry Nurse Other

Specialty _____

Mailing Address _____

City _____ State _____ Zip Code _____

Phone _____ Fax _____ E-Mail _____

Registration Fee

Registration fee partially covers continental breakfast, lunch and syllabus book

Physicians \$100.00 Nurses, Pharmacists, others \$40.00
 Fellows No Registration Fee *Industry \$500.00

*Person(s) employed by for-profit organizations such as pharmaceutical and biotech companies, and financial institutions

Payment may be made: MC Visa Discover Amex Check

Credit Card Number _____ Expiration Date _____ Security code (AmEx on front) _____

Name and address as it appears on Credit Card _____

Signature _____

Register online at www.Internationalcancernetwork.com

Please make checks payable to International Lung Cancer Network. Mail checks to PO Box 116609, Carrollton, TX 75011-6609

To reserve your place for the meeting, please complete the registration form and fax it 443-267-0016. If you have any questions please call 972-939-6206 or

E-mail: knaidu@internationalcancernetwork.com

If you wish to be removed from this fax list, please call 1-877-637-6872, or fax 443-267-0016.

Fax registration to:
443-267-0016
Mail registration to:
PO Box 116609
Carrollton, TX 75011-6609

International Congress for Lung Cancer, and Head & Neck Cancer

New York • September 25-26, 2009

Program Committee

Chandra P. Belani, MD
Penn State Cancer Institute, Hershey, PA

Walter Curran, MD
Emory Winship Cancer Institute, Atlanta, GA

Fadlo Khuri, MD
Emory Winship Cancer Institute, Atlanta, GA

Suresh Ramalingam, MD
Emory Winship Cancer Institute, Atlanta, GA

International Forum

Session Chair: Chandra P. Belani, MD

- 1:20 PM Phase III Studies in the USA
- 1:50 PM Treatment Strategies/Phase III Trials in Europe
- 2:20 PM Emerging Agents in Lung Cancer: A Look into the Future
- 2:50 PM Panel Discussion
- 3:00 PM Closing Remarks and Adjourn

Friday, September 25, 2009

- 7:00 AM Continental Breakfast and Registrations
- 7:55 AM Welcome and Introductions

Keynote Lectures

Session Chair: Chandra P. Belani, MD

- 8:00 AM Non-Small-Cell Lung Cancer: State of the Art
- 8:30 AM Small-Cell Lung Cancer: State of the Art
- 9:00 AM New Systemic Therapies for the Treatment of Head & Neck Cancer
- 9:30 AM Combined Multimodality Therapy of Lung Cancer, and Head & Neck Cancer
- 10:00 AM Panel Discussion
- 10:20 AM **BREAK**

EGFR and VEGF Targeted Agents

Session Chair: Suresh Ramalingam, MD

- 10:30 AM Erlotinib: Present Status and Future Perspectives, Molecular Markers and Patient Selection
- 11:00 AM Advanced and Metastatic Non-Small-Cell Lung Cancer: Implications of Bevacizumab
- 11:30 AM Other VEGF Targeted Agents and Multikinase Inhibitors in the Treatment of Lung Cancer
- 12:00 PM Panel Discussion
- 12:20 PM **LUNCH**

Saturday, September 26, 2009

- 7:00 AM Continental Breakfast
- 7:55 AM Opening Remarks

Imaging, Diagnosis and Surgical Intervention

Session Chair: Suresh Ramalingam, MD

- 8:00 AM Adjuvant Therapy for Non-Small-Cell Lung Cancer: Consensus and Controversies
- 8:25 AM N2 Disease: Consensus and Controversies
- 8:50 AM Lung Cancer Imaging –PET Scanning
- 9:15 AM Panel Discussion
- 9:35 AM **BREAK**

Emerging Novel Agents and Supportive Care Issues

Session Chair: Chandra P. Belani, MD

- 9:50 AM Supportive Care Issues in Lung Cancer, and Head & Neck Cancer
- 10:15 AM nab-Paclitaxel, Bortezomib and HDAC Inhibitors in the Treatment of Lung Cancer
- 10:40 AM Emerging Novel Agents in Lung Cancer (TRAIL and mTOR Inhibitors, MEK Inhibitors, AKT Inhibitors and IGF-IR Antibodies, and Small Molecule Inhibitors, c-met Inhibitors
- 11:10 AM Panel Discussion
- 11:30 AM Closing Remarks and Adjourn

Educational Grants

This Activity is Supported by Educational Grants from:

Genentech BioOncology

Lilly USA, LLC

Sanofi-Aventis

Bristol Myers Squibb/ImClone Systems

If you wish to be removed from this fax list, please call 1-877-637-6872, or fax 443-267-0016.